Key result
Tricuspid transcatheter edge-to-edge repair is an appealing therapy for severe tricuspid regurgitation, but not all screened patients are suitable candidates.
Why the study?
Despite T-TEER being an appealing therapy for patients with severe tricuspid regurgitation, not all patients screened are suitable candidates.
Answers are grounded in this paper and cite their sources.
Tricuspid transcatheter edge-to-edge repair (T-TEER) has emerged as a safe and effective therapy for patients with severe tricuspid regurgitation (TR).1 In The Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve Repair System (TRILUMINATE), T-TEER reduced TR severity and improved quality of life.1 Severe TR is associated with an increased risk of mortality and morbidity secondary to right ventricle (RV) failure and venous congestion.2 Despite T-TEER being an appealing therapy for patients with severe TR, not all patients screened are suitable candidates for T-TEER.
No takes yet. Share an insight, caveat, or question.
Hatab et al. (2023) studied Severe tricuspid regurgitation. Tricuspid transcatheter edge-to-edge repair (T-TEER) was evaluated. Tricuspid transcatheter edge-to-edge repair is an appealing therapy for severe tricuspid regurgitation, but not all screened patients are suitable candidates.
Synapse has enriched 10 related papers. Consider them for comparative context: